Treo Venture Partners is a venture capital firm that specializes in providing early-stage funding and support to innovative technology startups. The company focuses on partnering with entrepreneurs to build scalable and sustainable businesses that can make a significant impact in their respective industries.

Strategic Healthcare Investment Partners (S.H.I.P.) is now Treo Ventures. 

We focus on medical device and digital health innovation with significant clinical impact. We invest through our offices  in Silicon Valley, USA , and Dublin, Ireland.

Treo Ventures

We are excited to announce today that FDA has approved expanded labeling for Barostim, incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. 
 
“We are very pleased to receive this important validation from FDA of the long-term results of the post-market phase of the BeAT-HF clinical trial and excited we can now share this data with physicians and patients,” said Nadim Yared, CVRx CEO

Read the PR here: 
https://lnkd.in/ghM6tExk

ShiraTronics, Inc., a NuXcel spin off, and a Treo Ventures portfolio company is making great progress in first-in-human study. Congratulations to team ShiraTronics on this important milestone!

https://lnkd.in/gVB85gRR

Great additions to Team Noctrix Health, Inc. !!!!

Don't miss Treo Ventures Partner, Tracy Pappas, sharing her  experiences at "Models for Innovation" panel, June 16th at the Wilson Sonsini Goodrich & Rosati 30th Annual Medical Device Digital health Conference in San Francisco. 

#TreoVentures, #NuXcel, #MedTech , #innovationinhealthcare , #entrepreneurship, #startupecosystem, #venturecapital

Great progress being made by ShiraTronics, Inc., a NuXcel, Ltd spin off, and a Treo Ventures portfolio company targeting #Chronicmigraine. #Chronicmigraine affects millions across the globe, adversely impacting their daily activities. Some migraine sufferers refrain from identifying themselves as a migraine patients, due to social stigma and lack of compassion for their symptoms. For #migraine sufferers, we need to continue advocating on their behalf, and develop more effective therapies.

COM:TREOVP

Treo Venture Partners

Analysis Not Available